Home / Our Science
02 · Our Science
A cardiac myosin inhibitor, engineered for selectivity.
Our lead investigational candidate is designed to ease the excessive contraction that defines thickened heart muscle, at its source.
The mechanism
Reaching the motor of every heartbeat.
Contraction begins in the sarcomere, where a motor protein called myosin does the physical work of the heart. In HCM, that machinery runs too hot.
Sarcomere · myosin and actin cross-bridge cycle
What happens inside the muscle
Every heartbeat is a chemical and mechanical event repeated millions of times. Inside each muscle cell, thin filaments of actin slide past thick filaments of myosin. Myosin's small motor heads reach out, grip the actin, pull, and release, and it is the sum of countless such connections, called cross-bridges, that produces the force of a contraction.
In hypertrophic cardiomyopathy, too many of those cross-bridges form and hold, and the muscle contracts with more force than the heart needs. That excess force is not a side effect of the disease. It is close to its centre. It drives the muscle to overwork, contributes to the thickening over time, and leaves the chamber stiff and slow to relax.
A therapy that could reduce the number of active cross-bridges, gently and specifically, would be reaching the disease at the level where it actually operates. That is precisely what a cardiac myosin inhibitor is built to do.
Design principles
Three ideas the candidate is built around.
Targeting, selectivity and modality are not separate features. They are one coherent design decision, made in the service of a single disease.
Target the motor of contraction.
Rather than acting on the signalling around the heart, the candidate is designed to engage cardiac myosin itself, the motor at the centre of HCM's mechanics. By moderating the number of active force-generating connections, it aims to dial contraction back toward a healthier range from within the muscle.
Selective by design.
Selectivity is the point. The heart depends on finely balanced machinery, and a blunt intervention risks as much as it helps. The candidate is engineered to act on the specific protein driving the disease while leaving the surrounding system as undisturbed as possible, so that easing overactivity does not mean sacrificing the heart's normal work.
A small molecule for a defined disease.
As an orally available small molecule directed at a single, well characterised target, the candidate reflects EYEAM's whole posture: one mechanism, one disease, pursued in depth. The aim is to improve how the heart performs, how patients feel and function, and the outcomes that matter over the long course of the condition.
Why selectivity matters
Precision is not a luxury in the heart.
For a long time, the thickened, overworking heart of HCM was managed largely around the edges, easing symptoms without reaching the mechanics underneath them. Some approaches slowed the heart or relaxed blood vessels, offering relief without addressing why the muscle behaved as it did.
A mechanism-directed medicine changes that equation. But acting closer to the source raises the stakes of precision. The more directly a therapy touches the engine of the heartbeat, the more it matters that it touches only what it should, and by only as much as intended. Selectivity is what lets a medicine be both targeted and gentle.
Reach the cause, and reach only the cause. That is the whole ambition of selective inhibition.
Next
From mechanism to medicine.
A promising mechanism only matters if it holds up in people. See where the candidate stands in clinical development, and what the data have shown so far.